| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-860 | |
| Phytochemical name or plant extracts | Lycium barbarum extract | |
| PMID | 19373615 | |
| Literature evidence | Selective estrogen receptor modulators represent accepted therapy for estrogen receptor positive (ER+) breast cancer, exhibit adverse side effects, and reduce patient compliance. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Aqueous extract | |
| Source of phytochemicals or plant Extracts | Lycium barbarum | |
| Geographical availability | China North-Central, China South-Central, Inner Mongolia, Qinghai, Xinjiang | |
| Plant parts | Fruits | |
| Other cancers | Breast cancer | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | NA | |
| IC50 | NA | |
| Potency | Thus, MCF-7 cells retain their mitogenic and metabolic response to E2 and LB downregulates E2-stimulated growth via the formation of antiproliferative 2-OHE1 and accelerated conversion of mitogenic 16alpha-OHE1 to antimitogenic E3. | |
| Cell line/ mice model | MCF-7 | |
| Additional information | Treatment of E2 stimulated cells with LB exhibited a dose-dependent growth inhibition of 9.5%-42.8% at Day 3 and 33.9%-83.9% at Day 7. The 3-day inhibitory response to 1% LB (maximum cytostatic concentration) exhibited 84.8% increased E1, 3.6-fold increased 2-OHE1, 33.3% decreased 16alpha-OHE1, and 9.2-fold increased E3 formation. | |
| PubChem ID | NA | |
| Additional PMIDs | 24377707 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:816356-1 | |
| Safety | NA |